Serologic and molecular characteristics of hepatitis B virus infection in vaccinated schizophrenia patients in China

  • Yiying Wang School of Public Health, Medical College of Soochow University, Suzhou, China
  • Lugang Yu Suzhou Industrial Park Centers for Disease Control and Prevention, Suzhou, China
  • Hui Zhou Suzhou Industrial Park Centers for Disease Control and Prevention, Suzhou, China
  • Zhiwei Zhou School of Public Health, Medical College of Soochow University, Suzhou, China
  • Huijuan Zhu School of Public Health, Medical College of Soochow University, Suzhou, China
  • Yinghui Li Huai’an Third Hospital, Huai’an, China
  • Zhi Zheng Huai’an Third Hospital, Huai’an, China
  • Xinxin Li Zhangjiagang Women and Children Health Center, Suzhou, China
  • Chen Dong School of Public Health, Medical College of Soochow University, Suzhou, China
Keywords: hepatitis B virus, hepatitis B vaccine, schizophrenia, seroprevalence

Abstract

Introduction: Previous studies have indicated that the patients with psychiatric illness were at higher risk of hepatitis B virus (HBV) infection. However, the efficacy of hepatitis B vaccine in schizophrenia patients remains unclear.

Methodology: Between June 2014 and January 2015, 415 schizophrenia patients and 3,038 controls who had been routinely immunized as infants were recruited in the present study. Hepatitis B surface antigen (HBsAg), HBsAb, and HBV DNA were detected with commercial methods according to the manufacturer’s protocol. A 600-bp region of the S gene (region nt236–nt835) was amplified by nested polymerase chain reaction (PCR). The genotypes of isolated HBV were identified using phylogenetic analysis by the neighbor-joining algorithm in the software MEGA version 4.1.

Results: The seroprevalence of HBsAg in schizophrenia patients was 6.75%, which was significantly higher than 3.32% measured in controls. HBsAg prevalence was 7.94% in male schizophrenia patients and 5.47% in female schizophrenia patients, while it was only 4.04% in males and 2.08% in females in the control group. The HBsAb seroprevalence rate was 58.31% in schizophrenia patients and 59.94% in non-schizophrenia controls. Moreover, one HBV strain in the schizophrenia group presented I126S vaccine escape mutation (5.88%), while three HBV isolates showed Q129H, M133L, and G145R vaccine escape mutations in the control group (6.81%).

Conclusions: Schizophrenia patients are at higher risk for HBV infection, even those who had received routine immunization. Therefore, a booster HB vaccination targeted at schizophrenia patients should be considered in the future.

Published
2016-04-28
How to Cite
1.
Wang Y, Yu L, Zhou H, Zhou Z, Zhu H, Li Y, Zheng Z, Li X, Dong C (2016) Serologic and molecular characteristics of hepatitis B virus infection in vaccinated schizophrenia patients in China. J Infect Dev Ctries 10:427-431. doi: 10.3855/jidc.7377
Section
Brief Original Articles